Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis KS McCoy, AL Quittner, CM Oermann, RL Gibson, GZ Retsch-Bogart, ... American journal of respiratory and critical care medicine 178 (9), 921-928, 2008 | 436 | 2008 |
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis RL Gibson, J Emerson, S McNamara, JL Burns, M Rosenfeld, A Yunker, ... American journal of respiratory and critical care medicine 167 (6), 841-849, 2003 | 386 | 2003 |
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis GZ Retsch-Bogart, AL Quittner, RL Gibson, CM Oermann, KS McCoy, ... Chest 135 (5), 1223-1232, 2009 | 350 | 2009 |
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial F Ratjen, C Hug, G Marigowda, S Tian, X Huang, S Stanojevic, CE Milla, ... The lancet Respiratory medicine 5 (7), 557-567, 2017 | 320 | 2017 |
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis MM Treggiari, G Retsch-Bogart, N Mayer-Hamblett, U Khan, M Kulich, ... Archives of pediatrics & adolescent medicine 165 (9), 847-856, 2011 | 240 | 2011 |
Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol LA Lange, Y Hu, H Zhang, C Xue, EM Schmidt, ZZ Tang, C Bizon, ... The American Journal of Human Genetics 94 (2), 233-245, 2014 | 236 | 2014 |
Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis SD Davis, LA Fordham, AS Brody, TL Noah, GZ Retsch-Bogart, BF Qaqish, ... American journal of respiratory and critical care medicine 175 (9), 943-950, 2007 | 225 | 2007 |
Airway microbiota across age and disease spectrum in cystic fibrosis ET Zemanick, BD Wagner, CE Robertson, RC Ahrens, JF Chmiel, ... European Respiratory Journal 50 (5), 2017 | 215 | 2017 |
An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis CM Oermann, GZ Retsch‐Bogart, AL Quittner, RL Gibson, KS McCoy, ... Pediatric pulmonology 45 (11), 1121-1134, 2010 | 214 | 2010 |
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis CL Ordonez, NR Henig, N Mayer-Hamblett, FJ Accurso, JL Burns, ... American journal of respiratory and critical care medicine 168 (12), 1471-1475, 2003 | 198 | 2003 |
Progression of lung disease in preschool patients with cystic fibrosis S Stanojevic, SD Davis, G Retsch-Bogart, H Webster, M Davis, ... American journal of respiratory and critical care medicine 195 (9), 1216-1225, 2017 | 154 | 2017 |
Official American Thoracic Society technical standards: flexible airway endoscopy in children A Faro, RE Wood, MS Schechter, AB Leong, E Wittkugel, K Abode, ... American journal of respiratory and critical care medicine 191 (9), 1066-1080, 2015 | 152 | 2015 |
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy ET Zemanick, JK Harris, S Conway, MW Konstan, B Marshall, AL Quittner, ... Journal of Cystic Fibrosis 9 (1), 1-16, 2010 | 147 | 2010 |
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis RL Gibson, GZ Retsch‐Bogart, C Oermann, C Milla, J Pilewski, C Daines, ... Pediatric pulmonology 41 (7), 656-665, 2006 | 142 | 2006 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study MM Treggiari, M Rosenfeld, N Mayer-Hamblett, G Retsch-Bogart, ... Contemporary clinical trials 30 (3), 256-268, 2009 | 137 | 2009 |
Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes N Mayer-Hamblett, M Rosenfeld, RL Gibson, BW Ramsey, HD Kulasekara, ... American journal of respiratory and critical care medicine 190 (3), 289-297, 2014 | 134 | 2014 |
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to … R Deterding, G Retsch‐Bogart, L Milgram, R Gibson, C Daines, PL Zeitlin, ... Pediatric pulmonology 39 (4), 339-348, 2005 | 126 | 2005 |
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection GZ Retsch‐Bogart, JL Burns, KL Otto, TG Liou, K McCoy, C Oermann, ... Pediatric pulmonology 43 (1), 47-58, 2008 | 124 | 2008 |
Long term results of lung transplantation for cystic fibrosis TM Egan, FC Detterbeck, MR Mill, MS Bleiweis, R Aris, L Paradowski, ... European journal of cardio-thoracic surgery 22 (4), 602-609, 2002 | 114 | 2002 |
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial N Mayer-Hamblett, G Retsch-Bogart, M Kloster, F Accurso, M Rosenfeld, ... American journal of respiratory and critical care medicine 198 (9), 1177-1187, 2018 | 111 | 2018 |